focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Change

26 Jan 2023 08:00

Arix Bioscience PLC (ARIX)


Board Change

26-Jan-2023 / 07:00 GMT/BST

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

Board Change

London, 26 January 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, today announces Dr Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.

Peregrine Moncreiffe, Chairman of Arix, commented: “On behalf of the Board, I would like to thank Benny for the support he has shown to the Company since joining the Board last year and wish him well in his future endeavours.”

[ENDS]

 

For more information, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

 

About Arix Bioscience plc

 

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 



ISIN: GB00BD045071
Category Code: BOA
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 218423
EQS News ID: 1543761

 
End of Announcement EQS News Service


fncls.ssp?fn=show_t_gif&application_id=1543761&application_name=news&site_id=london_south_east
Date   Source Headline
22nd Jun 20224:45 pmEQSHolding(s) in Company
22nd Jun 20227:00 amEQSNotice of Investor Presentation
22nd Jun 20227:00 amEQSNotice of Investor Presentation
9th Jun 20227:00 amEQSUnaudited NAV for May 2022
9th Jun 20227:00 amEQSUnaudited NAV for May 2022
7th Jun 20224:45 pmEQSResult of Annual General Meeting 2022
12th May 20229:00 amRNSCommunications with Shareholders
12th May 20227:00 amRNSPublication of Annual Report & Notice of AGM
11th May 20227:01 amEQSUnaudited NAV for April
9th May 20223:29 pmEQSClinical Development Update from Portfolio Company LogicBio
5th May 20227:01 amEQSFinancial Results for the Year Ended 31 December 2021
4th May 20226:39 pmRNSStatement Regarding Arix Bioscience plc
4th May 20227:01 amEQSTR-1: Notification of major holdings
29th Apr 202210:45 amEQSUnaudited NAV and Notice of Financial Results
5th Apr 20224:29 pmEQSImara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
14th Mar 202211:32 amEQSCorporate update from portfolio company Harpoon Therapeutics
25th Feb 20225:30 pmRNSClosed Period Notification
24th Feb 20228:00 amRNSCompany Secretary Change
8th Feb 20227:20 amEQSTotal Voting Rights
2nd Feb 20221:06 pmEQSArix Bioscience PLC: Clinical development update from portfolio company LogicBio
22nd Dec 202111:05 amEQSArix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
17th Dec 202111:13 amEQSArix Bioscience PLC: Director/PDMR Shareholdings
17th Dec 20217:00 amRNSDirector/PDMR Shareholding
15th Dec 20218:14 amEQSArix Bioscience PLC: Depixus raises €30.6M (£26.1 million) in Series A Financing
13th Dec 20213:54 pmEQSArix Bioscience PLC: Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021
13th Dec 20213:51 pmEQSArix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021
17th Nov 20215:04 pmEQSImara Announces Interim Analysis Data From Forte Phase 2b Clinical Trial Of Tovinontrine (Imr-687) In Transfusion-Dependent Subjects With Beta-Thalassemia
8th Nov 20215:34 pmEQSTransaction in own shares
8th Nov 20211:00 pmEQSArix Bioscience PLC: Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
8th Nov 20217:01 amEQSArix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference
1st Nov 20217:01 amEQSTotal Voting Rights
29th Oct 20217:00 amEQSAura Biosciences prices Nasdaq IPO
18th Oct 20214:48 pmEQSLogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
18th Oct 20217:00 amEQSBusiness Update and Cancellation of Share Buyback
15th Oct 20215:30 pmEQSTransaction in own shares
14th Oct 20215:30 pmEQSTransaction in own shares
13th Oct 20215:30 pmEQSTransaction in own shares
13th Oct 20215:28 pmEQSTR1: Notification of Major Shareholding
12th Oct 20215:30 pmEQSTransaction in own shares
12th Oct 20211:02 pmEQSAura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting
11th Oct 20215:30 pmEQSTransaction in own shares
8th Oct 20215:30 pmEQSTransaction in own shares
8th Oct 202110:11 amEQSPyxis Oncology prices Nasdaq IPO - Update
8th Oct 20217:00 amEQSPyxis Oncology prices Nasdaq IPO
7th Oct 20215:30 pmEQSTransaction in own shares
6th Oct 20215:30 pmEQSTransaction in own shares
6th Oct 20217:00 amEQSBoard Changes
5th Oct 20215:30 pmEQSTransaction in own shares
4th Oct 20215:30 pmEQSTransaction in own shares
1st Oct 20215:30 pmEQSTransaction in own shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.